Heterogeneity for Stem Cell-related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2010 Jan 28

PMID 20103682

Citations 198

Authors

So Yeon Park

Hee Eun Lee

Hailun Li

Michail Shipitsin

Rebecca Gelman

Kornelia Polyak

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the expression of stem cell-related markers at the cellular level in human breast tumors of different subtypes and histologic stage.

Experimental Design: We performed immunohistochemical analyses of 12 proteins [CD44, CD24, ALDH1, vimentin, osteonectin, EPCR, caveolin 1, connexin 43, cytokeratin 18 (CK18), MUC1, claudin 7, and GATA3] selected based on their differential expression in breast cancer cells with more differentiated and stem cell-like characteristics in 47 cases of invasive ductal carcinoma (IDC) only, 135 cases of IDC with ductal carcinoma in situ (DCIS), 35 cases of DCIS with microinvasion, and 58 cases of pure DCIS. We also analyzed 73 IDCs with adjacent DCIS to determine the differences in the expression of markers by histology within individual tumors. CD44+/CD24- and CD24-/CD24+ cells were detected using double immunohistochemistry.

Results: CD44 and EPCR expression was different among the four histologic groups and was lower in invasive compared with in situ tumors, especially in luminal A subtype. The expression of vimentin, osteonectin, connexin 43, ALDH1, CK18, GATA3, and MUC1 differed by tumor subtype in some histologic groups. ALDH1-positive cells were more frequent in basal-like and HER2+ than in luminal tumors. CD44+/CD24- cells were detected in 69% of all tumors with 100% of the basal-like and 52% of HER2+ tumors having some of these cells.

Conclusions: Our findings suggest that in breast cancer, the frequency of tumor cells positive for stem cell-like and more differentiated cell markers varies according to tumor subtype and histologic stage.

Citing Articles

Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis.

Wang C, Wu L, Li X, Mao S, Wang Z, Xie H J Immunother Cancer. 2025; 13(2).

PMID: 40021214 PMC: 11873350. DOI: 10.1136/jitc-2024-009621.

Connexin-43 in Cancer: Above and Beyond Gap Junctions!.

Paunikar S, Tamagnone L Cancers (Basel). 2025; 16(24.

PMID: 39766090 PMC: 11674308. DOI: 10.3390/cancers16244191.

The treatment landscape of triple-negative breast cancer.

Hu Y, Wang C, Liang H, Li J, Yang Q Med Oncol. 2024; 41(10):236.

PMID: 39210220 DOI: 10.1007/s12032-024-02456-9.

Exploring the association between circulating endothelial protein C receptor and disease activity of rheumatoid arthritis in a pilot study.

Xue M, Lin H, Lynch T, Bereza-Malcolm L, Sinnathurai P, Thomas R Rheumatol Adv Pract. 2024; 8(3):rkae096.

PMID: 39184533 PMC: 11343369. DOI: 10.1093/rap/rkae096.

E3 ubiquitin ligase BCA2 promotes breast cancer stemness by up-regulation of SOX9 by LPS.

Zheng M, Liu W, Zhang R, Jiang D, Shi Y, Wu Y Int J Biol Sci. 2024; 20(7):2686-2697.

PMID: 38725852 PMC: 11077363. DOI: 10.7150/ijbs.92338.

References

Graff J, Gabrielson E, Fujii H, Baylin S, Herman J . Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem. 2000; 275(4):2727-32. DOI: 10.1074/jbc.275.4.2727. View

Polyak K . Breast cancer: origins and evolution. J Clin Invest. 2007; 117(11):3155-63. PMC: 2045618. DOI: 10.1172/JCI33295. View

Xiao Y, Ye Y, Yearsley K, Jones S, Barsky S . The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol. 2008; 173(2):561-74. PMC: 2475792. DOI: 10.2353/ajpath.2008.071214. View

Fillmore C, Kuperwasser C . Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008; 10(2):R25. PMC: 2397524. DOI: 10.1186/bcr1982. View

Wright M, Calcagno A, Salcido C, Carlson M, Ambudkar S, Varticovski L . Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008; 10(1):R10. PMC: 2374965. DOI: 10.1186/bcr1855. View

Shackleton M, Quintana E, Fearon E, Morrison S . Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009; 138(5):822-9. DOI: 10.1016/j.cell.2009.08.017. View

Asselin-Labat M, Sutherland K, Barker H, Thomas R, Shackleton M, Forrest N . Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol. 2006; 9(2):201-9. DOI: 10.1038/ncb1530. View

Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha R . Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006; 7:127. PMC: 1489944. DOI: 10.1186/1471-2164-7-127. View

Honeth G, Bendahl P, Ringner M, Saal L, Gruvberger-Saal S, Lovgren K . The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008; 10(3):R53. PMC: 2481503. DOI: 10.1186/bcr2108. View

10.

Campbell L, Polyak K . Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle. 2007; 6(19):2332-8. DOI: 10.4161/cc.6.19.4914. View

11.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

12.

Sheridan C, Kishimoto H, Fuchs R, Mehrotra S, Bhat-Nakshatri P, Turner C . CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006; 8(5):R59. PMC: 1779499. DOI: 10.1186/bcr1610. View

13.

Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, Wicha M . Cancer stem cells in breast: current opinion and future challenges. Pathobiology. 2008; 75(2):75-84. PMC: 2789397. DOI: 10.1159/000123845. View

14.

Polyak K, Hahn W . Roots and stems: stem cells in cancer. Nat Med. 2006; 12(3):296-300. DOI: 10.1038/nm1379. View

15.

Sarrio D, Rodriguez-Pinilla S, Hardisson D, Cano A, Moreno-Bueno G, Palacios J . Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008; 68(4):989-97. DOI: 10.1158/0008-5472.CAN-07-2017. View

16.

Ivanova N, Dimos J, Schaniel C, Hackney J, Moore K, Lemischka I . A stem cell molecular signature. Science. 2002; 298(5593):601-4. DOI: 10.1126/science.1073823. View

17.

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

18.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

19.

Heppner G, Miller B . Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev. 1983; 2(1):5-23. DOI: 10.1007/BF00046903. View

20.

Shipitsin M, Campbell L, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J . Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007; 11(3):259-73. DOI: 10.1016/j.ccr.2007.01.013. View